Prokidney (PROK) Other Accumulated Expenses (2021 - 2026)
Prokidney's (PROK) quarterly Other Accumulated Expenses came in at $2.0 million in Q2 2026, up 62.58% year-over-year from $1.2 million in Q2 2025, and up 42.63% quarter-over-quarter from $1.4 million in Q1 2026.
Analysis
Prokidney (PROK) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Other Accumulated Expenses for 6 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Accumulated Expenses rose 62.58% year-over-year to $2.0 million in Q2 2026; TTM through Jun 2026 was $2.0 million, a 62.58% increase from a year earlier, with the FY2025 full-year figure at $667000.0, down 65.1% from the prior year.
- Other Accumulated Expenses was $2.0 million for Q2 2026 at Prokidney, up from $1.4 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $2.6 million in Q3 2024 and troughed at $21000.0 in Q4 2022.
- A 5-year average of $1.3 million and a median of $1.5 million in 2023 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses plunged 85.91% in 2022 and jumped 7214.29% in 2023, its largest moves.
- Over 5 years, Other Accumulated Expenses stood at $21000.0 in 2022, then jumped by 7214.29% to $1.5 million in 2023, then gained by 24.41% to $1.9 million in 2024, then sank by 65.1% to $667000.0 in 2025, then soared by 194.45% to $2.0 million in 2026.
- The last three Other Accumulated Expenses figures came in at $2.0 million (Q2 2026), $1.4 million (Q1 2026), and $667000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 667,000.00 |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 924,000.00 |
| Jun 30, 2023 | 542,000.00 |
| Mar 31, 2023 | 450,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 537,000.00 |
| Dec 31, 2021 | 149,000.00 |